ACRS Earnings Date: Nov 5, 2026 (Estimated) — Aclaris Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ACRS's next earnings date?
Aclaris Therapeutics, Inc. (ACRS) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.16 on revenue of $1.2M.
How did ACRS do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Aclaris Therapeutics, Inc. posted EPS of -$0.15 versus the -$0.16 estimate, a beat of 6.3%. Revenue was $1.6M against a $1.4M estimate. The stock's 1-day post-earnings move was -4.2%.
How much does ACRS stock move after earnings?
ACRS beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.0% (up or down) in the day after earnings.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.16 | -0.15 | +6.25% | $1.6M | ✅ Beat | -4.25% | -8.18% | -6.45% |
| 2026-05-07 | Q1 2026 | -0.16 | -0.15 | +6.25% | $2.0M | ✅ Beat | +1.67% | +6.49% | -8.79% |
| 2026-02-26 | Q4 2025 | -0.14 | -0.16 | -14.29% | $1.3M | ❌ Miss | -5.44% | -6.34% | +6.34% |
| 2025-11-06 | Q3 2025 | -0.14 | -0.12 | +14.29% | $3.3M | ✅ Beat | +0.44% | +6.64% | +29.20% |
| 2025-02-27 | Q4 2024 | -0.27 | -0.10 | +62.96% | $9.2M | ✅ Beat | -7.14% | -11.90% | -22.86% |
| 2024-11-06 | Q3 2024 | -0.01 | -0.11 | -1000.00% | $4.3M | ❌ Miss | +1.80% | +15.32% | +71.62% |
| 2024-08-07 | Q2 2024 | -0.20 | -0.15 | +25.00% | $2.8M | ✅ Beat | -2.46% | -2.46% | -3.28% |
| 2024-05-07 | Q1 2024 | -0.29 | -0.24 | +17.24% | $2.4M | ✅ Beat | -8.96% | -11.94% | -23.13% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $1.6M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| License and Service | 78.1% | $1.3M | -4.6% | $10.7M | $1.0M | $1.3M | $2.8M |
| Contract research | 21.9% | $356K | -19.5% | $1.2M | $445K | $442K | $485K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.